A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer
Latest Information Update: 02 Feb 2023
At a glance
- Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms TNACITY
- Sponsors Abraxis BioScience; Celgene Corporation
- 16 Dec 2021 This trial has been discontinued in Austria, Germany, Portugal, UK and Greece. Whereas, completed in France, Italy and Spain according to European Clinical Trials Database record.
- 06 Jun 2018 Results from phase II portion of the study published in the Annals of Oncology.
- 30 Mar 2017 Status changed from active, no longer recruiting to completed.